Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

Inclusion Criteria

• •Non-resectable pancreatic cancer
• •* Biopsy proven adenocarcinoma compatible with pancreatic origin (primary tumor or metastasis)
• •* If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the pancreas
• •* Deemed non-resectable at a multidisciplinary conference
• •Candidate to standard systemic therapy, defined as one of
• •* Gemcitabine monotherapy,
• •* Gemcitabine and nab-paclitaxel combination,
• •* Gemcitabine and capecitabine combination,
• •* 5-fluorouracil, oxaliplatin and irinotecan combination (FOLFIRINOX), or
• •* New standard treatments approved by the multidisciplinary cancer group 'Danish Pancreatic Cancer Group' in the inclusion period.
• •Measurable disease according to RECIST 1.1
• •ECOG performance status 0-2
• •Age at least 18 years
• •Adequate bone marrow, liver and renal function allowing systemic chemotherapy
• •* Absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l
• •* Bilirubin ≤ 3 x upper normal value and alanine aminotransferase ≤ 5 x upper normal value
• •* Calculated or measured renal glomerular filtration rate at least 30 mL/min
• •Contraception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable
• •Written and orally informed consent